Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for "Re-examination of New Drugs"
Phase of Trial: Phase IV
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HCV PMS
- Sponsors AbbVie
- 24 Jul 2019 Status changed from active, no longer recruiting to completed.
- 22 Apr 2019 Planned End Date changed from 31 Dec 2022 to 30 Sep 2019.
- 22 Apr 2019 Planned primary completion date changed from 31 Dec 2022 to 30 Sep 2019.